This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: A blank-check entity formed by biotechnology investor Cormorant Asset Management has raised $150 million in an initial public offering meant to support a future merger with a privately held company. The special purpose acquisition company or “SPAC,” called Helix Acquisition Corp. III, sold 15 million shares at $10 apiece, some 2.5 million more sh ...